Streamlining the design of promising clinical trials: In-vitro testing of antithrombotic regimens and multiple agonists of platelet activation

Coronary Artery Disease

Volumn 20, Issue 2, 2009, Pages 175-178

  Schneider, David J ^a   Sobel, Burton E ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

Anticoagulant; Antiplatelet agent; Platelet function testing

Indexed keywords

ADENOSINE DIPHOSPHATE; CANGRELOR; CONVULXIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; HEPARIN; HIRULOG; PADGEM PROTEIN; THROMBIN; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR DERIVATIVE; ADENOSINE PHOSPHATE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FIBRINOLYTIC AGENT; HIRUDIN DERIVATIVE; LECTIN; PEPTIDE; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN; SNAKE VENOM;

ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG BLOOD LEVEL; DRUG SCREENING; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; ANIMAL; BLOOD; BLOOD CLOTTING PARAMETERS; CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECT; METABOLISM; METHODOLOGY; PILOT STUDY; THROMBOCYTE;

ADENOSINE DIPHOSPHATE; ADENOSINE MONOPHOSPHATE; ANIMALS; BLOOD PLATELETS; CLINICAL TRIALS AS TOPIC; CORONARY ARTERY DISEASE; CROTALID VENOMS; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; FIBRINOLYTIC AGENTS; FLOW CYTOMETRY; HEPARIN; HIRUDINS; HUMANS; LECTINS, C-TYPE; P-SELECTIN; PEPTIDE FRAGMENTS; PEPTIDES; PILOT PROJECTS; PLATELET ACTIVATING FACTOR; PLATELET ACTIVATION; PLATELET FUNCTION TESTS; RECOMBINANT PROTEINS; RESEARCH DESIGN; THROMBIN;

EID: 66349137731     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCA.0b013e32831edcd1     Document Type: Article

References (11)

1. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med 2008; 359:938-949.
2. Daví G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357:2482-2494.
3. Schneider DJ, Aggarwal A. Development of glycoprotein IIb-IIIa antagonists, translation of pharmacodynamic effects into clinical benefit. Expert Rev Cardiovasc Ther 2004; 2:903-913.
4. André P, LaRocca T, Delaney SM, Lin PH, Vincent D, Sinha U, et al. Anticoagulants (thrombin inhibitors) and aspirin synergize with P2Y12 receptor antagonism in thrombosis. Circulation 2003; 108: 2697-2703.
5. Gilchrist IC, O'Shea JC, Kosoglou T, Jennings LK, Lorenz TJ, Kitt MM, et al. Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention. Circulation 2001; 104:406-411.
6. Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, et al.; REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003; 289:853-863.
7. Schneider DJ, Keating FK, Sobel BE. Greater inhibitory effects of bivalirudin compared with unfractionated heparin plus eptifibitide on thrombin-induced platelet activation. Coron Artery Dis 2006; 17:471-476.
8. Achyuthan KE, Dobson JV, Greenberg CS. Gly-Pro-Arg-Pro modifies the glutamine residues in the alpha-and gamma-chains of fibrinogen: inhibition of transglutaminase cross-linking. Biochim Biophys Acta 1986; 872:261-268.
9. Schneider DJ, Whitaker DA, Sobel BE. Efficiency in clinical research: assessment in vitro of potential anti-thrombotic drug interactions. Coron Artery Dis 2004; 15:177-181.
10. Schneider DJ, Herrmann HC, Lakkis N, Aguirre F, Lo M-W, Aggarwal A, et al. Association of greater bolus doses with increased concentrations of tirofiban in blood and correlation with the inhibition of platelet aggregation. Am J Cardiol 2003; 91:334-336.
11. Keating FK, Dauerman HL, Whitaker DA, Sobel BE, Schneider DJ. Increased expression of platelet P-selectin and formation of platelet-leukocyte aggregates in blood from patients treated with unfractionated heparin plus eptifibatide compared with bivalirudin. Thromb Res 2006; 118:361-369.